Immunotherapy in Treating Patients With Metastatic Breast Cancer
Maneno muhimu
Kikemikali
Maelezo
OBJECTIVES:
- Evaluate the ability of active immunotherapy with carcinoembryonic antigen (CEA) RNA pulsed dendritic cells to induce CEA specific T cells in patients with metastatic breast cancer in complete remission following peripheral blood stem cell transplant.
- Determine the clinical efficacy in terms of overall and recurrence free survival of immunotherapy with CEA RNA pulsed dendritic cells in this patients population.
OUTLINE: Dendritic cells are taken from the leukapheresis product obtained during the peripheral blood stem cell transplant procedure performed prior to treatment on this study. The dendritic cells are pulsed with carcinoembryonic antigen (CEA) RNA. Approximately 60-90 days after the peripheral blood stem cell transplant, patients receive CEA RNA pulsed dendritic cells IV every 3 weeks for a total of 4 doses. Patients undergo a second leukopheresis after the last dose of immunotherapy to obtain specimens for immunologic tests.
Patients are followed every 3 months for the first year and annually thereafter.
PROJECTED ACCRUAL: A total of 14-26 patients will be accrued for this study within 2 years.
Tarehe
| Imethibitishwa Mwisho: | 10/31/2013 |
| Iliyowasilishwa Kwanza: | 10/31/1999 |
| Uandikishaji uliokadiriwa Uliwasilishwa: | 04/23/2003 |
| Iliyotumwa Kwanza: | 04/24/2003 |
| Sasisho la Mwisho Liliwasilishwa: | 11/04/2013 |
| Sasisho la Mwisho Lilichapishwa: | 11/05/2013 |
| Tarehe halisi ya kuanza kwa masomo: | 05/31/1998 |
| Tarehe ya Kukamilisha Msingi iliyokadiriwa: | 10/31/2002 |
| Tarehe ya Kukamilisha Utafiti: | 10/31/2002 |
Hali au ugonjwa
Uingiliaji / matibabu
Biological: carcinoembryonic antigen RNA-pulsed DC cancer vaccine
Awamu
Vikundi vya Arm
| Mkono | Uingiliaji / matibabu |
|---|---|
| Experimental: carcinoembryonic antigen RNA-pulsed DC cancer vaccine carcinoembryonic antigen RNA-pulsed DC cancer vaccine | Biological: carcinoembryonic antigen RNA-pulsed DC cancer vaccine Approximately 60-90 days after the peripheral blood stem cell transplant, patients receive CEA RNA pulsed dendritic cells IV every 3 weeks for a total of 4 doses. |
Vigezo vya Kustahiki
| Zama zinazostahiki Kujifunza | 18 Years Kwa 18 Years |
| Jinsia Inastahiki Kujifunza | All |
| Hupokea Wajitolea wa Afya | Ndio |
| Vigezo | DISEASE CHARACTERISTICS: - Histologically confirmed metastatic breast cancer that expresses carcinoembryonic antigen (CEA) - At least 25% of the tumor cells must stain positive for CEA with at least moderate intensity - Must have achieved either partial response or complete response after high dose chemotherapy and peripheral blood stem cell transplant - Hormone receptor status: - Not specified PATIENT CHARACTERISTICS: Age: - 18 and over Menopausal status: - Not specified Performance status: - Karnofsky 70-100% Life expectancy: - Greater than 6 months Hematopoietic: - Absolute neutrophil count at least 1000/mm^3 - Absolute lymphocyte count at least 1000/mm^3 - Hemoglobin at least 9 mg/dL - Platelet count at least 100,000/mm^3 Hepatic: - Bilirubin less than 2.0 mg/dL - No serious ongoing chronic or acute hepatic disease Renal: - Creatinine less than 2.5 mg/dL Cardiovascular: - No serious ongoing chronic or acute cardiac disease (New York Heart Association class III or IV) Pulmonary: - No serious ongoing chronic or acute pulmonary illness such as asthma, chronic obstructive pulmonary disease, or radiation or drug induced pneumonitis Other: - No other prior or concurrent malignancy except nonmelanoma skin cancer or controlled superficial bladder cancer within the past 5 years - No history of autoimmune disease such as inflammatory bowel disease, systemic lupus erythematosus, rheumatoid arthritis, ankylosing spondylitis, scleroderma, or multiple sclerosis - No inflammatory bowel condition such as active infectious enteritis or eosinophilic enteritis - No active acute or chronic infection such as urinary tract infection, HIV, or viral hepatitis - Not pregnant or nursing PRIOR CONCURRENT THERAPY: Biologic therapy: - See Disease Characteristics - No concurrent immunotherapy Chemotherapy: - See Disease Characteristics - No concurrent chemotherapy Endocrine therapy: - At least 4 weeks since steroids - No concurrent steroid therapy Radiotherapy: - No concurrent radiotherapy Surgery: - Not specified Other: - No concurrent immunosuppressive agents such as azathioprine or cyclosporine A |
Matokeo
Hatua za Matokeo ya Msingi
1. Evaluate the ability of active immunotherapy with carcinoembryonic antigen (CEA) RNA pulsed dendritic cells to induce CEA specific T cells in patients with metastatic breast cancer in complete remission following peripheral blood stem cell transplant. [Following administration of 4 IV vaccine doses (1 vaccine administered every 3 weeks)]
Hatua za Matokeo ya Sekondari
1. Determine the clinical efficacy in terms of overall and recurrence free survival of immunotherapy with CEA RNA pulsed dendritic cells in this patients population. [Following administration of 4 IV vaccine doses (1 vaccine administered every 3 weeks)]
